Halozyme Therapeutics Inc. (NASDAQ: HALO)’s stock price has decreased by -4.64 compared to its previous closing price of 42.00. Despite this, the company has experienced a -5.79% fall in its stock price over the last five trading sessions. Barron’s reported on 04/13/22 that Antares Pharma Stock Soars After $960 Million Halozyme Buyout
Is It Worth Investing in Halozyme Therapeutics Inc. (NASDAQ: HALO) Right Now?
Halozyme Therapeutics Inc. (NASDAQ: HALO) has a higher price-to-earnings ratio of 27.79x compared to its average ratio. compared to its average ratio and a 36-month beta value of 1.27. Analysts have mixed views on the stock, with 8 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 1 as “sell.”
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
The average price point forecasted by analysts for Halozyme Therapeutics Inc. (HALO) is $56.11, which is $16.57 above the current market price. The public float for HALO is 133.75M, and currently, short sellers hold a 5.16% ratio of that float. The average trading volume of HALO on March 16, 2023 was 1.24M shares.
HALO’s Market Performance
HALO stock saw a decrease of -5.79% in the past week, with a monthly decline of -18.43% and a quarterly a decrease of -31.01%. The volatility ratio for the week is 3.98%, and the volatility levels for the last 30 days are 3.31% for Halozyme Therapeutics Inc. (HALO). The simple moving average for the last 20 days is -14.25% for HALO stock, with a simple moving average of -16.44% for the last 200 days.
Analysts’ Opinion of HALO
Many brokerage firms have already submitted their reports for HALO stocks, with Morgan Stanley repeating the rating for HALO by listing it as a “Overweight.” The predicted price for HALO in the upcoming period, according to Morgan Stanley is $65 based on the research report published on December 21st of the previous year 2022.
Wells Fargo, on the other hand, stated in their research note that they expect to see HALO reach a price target of $65. The rating they have provided for HALO stocks is “Overweight” according to the report published on November 28th, 2022.
Morgan Stanley gave a rating of “Overweight” to HALO, setting the target price at $50 in the report published on September 09th of the previous year.
HALO Trading at -19.88% from the 50-Day Moving Average
After a stumble in the market that brought HALO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.64% of loss for the given period.
Volatility was left at 3.31%, however, over the last 30 days, the volatility rate increased by 3.98%, as shares sank -17.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -29.61% lower at present.
During the last 5 trading sessions, HALO fell by -5.79%, which changed the moving average for the period of 200-days by -14.06% in comparison to the 20-day moving average, which settled at $46.27. In addition, Halozyme Therapeutics Inc. saw -29.61% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at HALO starting from Torley Helen, who sale 10,000 shares at the price of $42.73 back on Mar 09. After this action, Torley Helen now owns 623,666 shares of Halozyme Therapeutics Inc., valued at $427,270 using the latest closing price.
Torley Helen, the PRESIDENT AND CEO of Halozyme Therapeutics Inc., sale 10,000 shares at $43.26 during a trade that took place back on Mar 08, which means that Torley Helen is holding 623,666 shares at $432,590 based on the most recent closing price.
Stock Fundamentals for HALO
Current profitability levels for the company are sitting at:
- +43.85 for the present operating margin
- +72.36 for the gross margin
The net margin for Halozyme Therapeutics Inc. stands at +30.62. Equity return is now at value 98.60, with 12.20 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 5.65.
To put it simply, Halozyme Therapeutics Inc. (HALO) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.